Sterling Capital Management LLC Black Diamond Therapeutics, Inc. Transaction History
Sterling Capital Management LLC
- $7.74 Trillion
- Q3 2024
A detailed history of Sterling Capital Management LLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Sterling Capital Management LLC holds 64 shares of BDTX stock, worth $207. This represents 0.0% of its overall portfolio holdings.
Number of Shares
64Holding current value
$207% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BDTX
# of Institutions
105Shares Held
46.1MCall Options Held
318KPut Options Held
263K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$34.8 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$27.6 Million0.62% of portfolio
-
Vestal Point Capital, LP New York, NY5.03MShares$16.3 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$14.4 Million1.48% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$10.4 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $118M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...